Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced that a broad portfolio of its Alethia molecular assays has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.
Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit
The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS Enzymatic DNA Fragmentation Kit. The kit is designed for ambient-temperature (15-25⁰C) shipping and storage, eliminating the need for cold-chain requirements and helping laboratories simplify their NGS sample preparation workflows.
Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare Test KitsCINCINNATI, OH / ACCESSWIRE / September 1, 2021 / Meridian Bioscience, Inc. (
NASDAQ:VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. ("Magellan"), expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead Test Kits, and LeadCare Ultra® Blood Lead Test Kits (the "LeadCare Test Kits") for the
Meridian Bioscience to Present at the H. C. Wainwright 23rd Annual Global Investment ConferenceCINCINNATI, OH / ACCESSWIRE / August 30, 2021 / Meridian Bioscience, Inc. (
NASDAQ:VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainwright 23rd Annual Global Investment Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on September 13, 2021 at 7:00 am ET. A link to access the pre-recorded presentation will be
